Clinical Trials
25 trialsNCT04936529 2026-05-07
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07537400 2026-04-17
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
Shaare Zedek Medical Center
Phase 2 Not yet recruiting
NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT06450041 2026-03-23
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT03363373 2026-02-19
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Y-mAbs Therapeutics
Phase 2 Recruiting
NCT06528496 2026-02-10
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT01757626 2026-01-07
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT03033303 2025-10-07
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03189706 2025-07-02
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT02169609 2024-04-22
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Phase 2 Completed
NCT06047535 2023-09-21
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
SciClone Pharmaceuticals
Phase 4 Not yet recruiting
NCT02641782 2022-11-04
NB2013-HR
University of Cologne
Phase 2 Terminated
NCT04909515 2022-09-01
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Y-mAbs Therapeutics
Phase 2 Withdrawn
NCT02786719 2020-03-12
SPRING
Baylor College of Medicine
Phase NA Completed
NCT02100930 2020-02-28
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01334515 2019-10-21
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Completed
NCT02173093 2019-01-29
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
University of Virginia
Phase 1/2 Unknown
NCT02933333 2018-10-17
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4 Unknown
NCT02130869 2017-12-22
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01592045 2015-09-23
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
United Therapeutics
Phase 1/2 Completed
NCT00003093 2014-08-01
Combination Chemotherapy in Treating Children With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT00969722 2013-03-08
A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients
United Therapeutics
Phase 2 Terminated
NCT00005576 2013-01-16
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Completed